| Product Specs | Description |
|---|---|
| Manufacturer Name | Takeda |
| Indications | Indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. |
| Contraindications | Anaphylactic or severe systemic reaction to antihemophilic factor or VWF preparations. |
| Ratio of VWF: RCO to FVIII | no significant traces of VWF |
| Viral Safety Process | Affinity chromatography, ion-exchange chromatography,solvent/detergent, nanofiltration. |
| Product Half-Life | Mean: 12.2 (range: 8.4 to 17.4) hours |
| Product Recovery Percentage | 2.0 IU/dL rise per IUkg |
| Manufacturing Methods | Pooled human plasma |
| Storage Requirements/Shelf Life |
|
| Nominal Vial Size & Diluent Volume | 250 IU/10 mL 500 IU/10 mL 1000 IU/10 mL 1700 IU/10 mL |
